Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review

Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review

The efficacy of first-and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC patients with the EGFR L861Q mutation has been studied previously. However, there is little evidence on the efficacy of osimertinib in NSCLC patients with uncommon mutations....

Full description

Bibliographic Details
Main Authors: Ruiting Lin, Ruilian Chen, Zhiqiang Chen, Leihao Hu, Wei Guo, Zexin Zhang, Lizhu Lin, Hanrui Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
epidermal growth factor receptor
non-small-cell lung cancer
osimertinib
compound mutation
tyrosine kinase inhibitor
uncommon mutation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.731572/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.731572/full

Similar Items